三元生物(301206) - 2024 Q1 - 季度财报(更正)

Financial Performance - The company's revenue for Q1 2024 reached ¥191,894,599.16, representing a 65.03% increase compared to ¥116,276,458.04 in the same period last year[4] - Net profit attributable to shareholders was ¥24,247,672.28, a significant increase of 210.54% from ¥7,808,194.59 year-on-year[4] - Basic and diluted earnings per share both increased to ¥0.12, reflecting a 200.00% rise from ¥0.04 in the same quarter last year[4] - Total operating revenue for the current period reached ¥191,894,599.16, a significant increase from ¥116,276,458.04 in the previous period, representing a growth of approximately 64.8%[23] - Net profit for the current period was ¥24,247,672.28, compared to ¥7,808,194.59 in the previous period, reflecting a growth of approximately 210.5%[24] Cash Flow - The net cash flow from operating activities surged by 744.81% to ¥22,158,704.92, up from ¥2,622,930.65 in the previous year[4] - Total cash inflow from operating activities reached 202,928,457.01 yuan, up from 143,143,501.00 yuan, reflecting a growth of 41.6%[26] - Cash outflow for operating activities was 180,769,752.09 yuan, compared to 140,520,570.35 yuan, an increase of 28.6%[26] - Net cash flow from investing activities was -32,224,720.95 yuan, an improvement from -328,183,999.71 yuan in the previous period[27] - The company received 18,871,599.36 yuan in tax refunds, up from 12,477,423.01 yuan, indicating a growth of 51.1%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,879,388,138.47, a 1.49% increase from ¥4,807,533,905.12 at the end of the previous year[4] - Current assets totaled ¥351,020,607.19, up from ¥321,813,853.97, which is an increase of approximately 9.0%[21] - The total liabilities increased to ¥320,010,491.34 from ¥272,403,930.27, indicating a rise of about 17.5%[22] - The total equity attributable to the parent company increased to ¥4,559,377,647.13 from ¥4,535,129,974.85, a growth of about 0.5%[22] Operating Costs and Expenses - The company reported a 44.95% increase in operating costs, primarily due to higher sales volume[8] - Total operating costs amounted to ¥194,873,387.02, up from ¥135,685,668.54, indicating an increase of about 43.5%[23] - Research and development expenses rose by 34.31%, indicating the company's commitment to enhancing competitiveness through increased market expansion and R&D investment[8] - The company's research and development expenses were ¥15,833,077.03, compared to ¥11,788,523.18 in the previous period, reflecting an increase of approximately 34.5%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,093, with the largest shareholder holding 46.14% of the shares[10] - The total number of shares held by the top 10 shareholders is 98,780,906, with a significant portion being subject to lock-up agreements[15] - The largest shareholder, 聂在建, holds 92,946,000 shares, which are subject to a lock-up until August 10, 2025[15] - The company has a total of 127,969 shares released from lock-up during the reporting period[15] Management and Governance - The company plans to use up to RMB 240 million of temporarily idle raised funds for cash management within 12 months from the approval date of the shareholders' meeting[16] - The company intends to utilize up to RMB 100 million of temporarily idle self-owned funds for cash management, also within a 12-month period from the shareholders' meeting approval[17] - The company's management is authorized to make investment decisions within the approved limits for cash management[18] Miscellaneous - The company’s financial reports are prepared as of March 31, 2024, indicating ongoing financial assessments[19] - The first quarter report was not audited, indicating a preliminary financial assessment[28] - The company did not report any net increase in customer deposits or interbank placements during the period[26]